Table 4.
Incidence rates of adverse events after medication
| Solifenacin succinate |
|||
|---|---|---|---|
| Adverse events* | 5 mg qd (N= 118), n (%) | 10 mg qd (N= 118), n (%) | Tolterodine 2 mg bid (N = 118), n (%) |
| Gastrointestinal disorders | 22 (18.64) | 42 (35.59) | 30 (25.42) |
| Dry mouth | 9 (7.63) | 23 (19.49) | 22 (18.64) |
| Constipation | 8 (6.78) | 17 (14.41) | 3 (2.54) |
| Dyspepsia | 3 (2.54) | 4 (3.39) | 2 (1.69) |
| Abdominal pain upper | 2 (1.69) | 4 (3.39) | 1 (0.85) |
| Eye disorders | 17 (14.41) | 25 (21.19) | 18 (15.25) |
| Vision blurred | 16 (13.56) | 19 (16.10) | 12 (10.17) |
| Dry eye NOS | 0 (0.00) | 1 (0.85) | 3 (2.54) |
| Renal and urinary disorders | 6 (5.08) | 10 (8.47) | 14 (11.86) |
| Difficulty in micturition | 1 (0.85) | 6 (5.08) | 6 (5.08) |
| Urine flow decreased | 3 (2.54) | 3 (2.54) | 3 (2.54) |
| Vesical tenesmus | 1 (0.85) | 1 (0.85) | 3 (2.54) |
| Infections and infestations | 7 (5.93) | 5 (4.24) | 6 (5.08) |
| Cystitis NOS | 3 (2.54) | 2 (1.69) | 2 (1.69) |
| Nasopharyngitis | 1 (0.85) | 1 (0.85) | 3 (2.54) |
| Nervous system disorders | 2 (1.69) | 3 (2.54) | 3 (2.54) |
| Injury, poisoning and procedural complications | 0 (0.00) | 5 (4.24) | 2 (1.69) |
| General disorders and administration site conditions | 0 (0.00) | 1 (0.85) | 4 (3.39) |
| Skin and subcutaneous tissue disorders | 1 (0.85) | 3 (2.54) | 1 (0.85) |
*Dictionary: MedDRA 5.0 (incidence of AEs ≥ 2.0%). NOS, not otherwise specified; AEs, adverse events.